Inceptive Valuation, Funding & Investors

Vedanta Biosciences is a Cambridge, Massachusetts-based biotechnology company engineering microbiome immunotherapies for autoimmune, inflammatory, and infectious diseases. It develops consortia of live bacteria selected via proprietary assays from human donor samples, manufactured in cGMP facilities for oral administration. Vedanta's lead candidate VE202 advances in Phase 2 for graft-versus-host disease, with prior programs partnered to Janssen for Crohn's disease. Founded in 2010 as Seres spin-out, it maintains a library of over 1,000 bacterial strains and datasets from interventional studies.

Readline is a Shenzhen-headquartered biopharmaceutical firm pioneering enzyme-directed evolution for green manufacturing of active pharmaceutical ingredients. Specializing in peptides, carbohydrates, and nucleic acids, it supplies intermediates for medicines, cosmetics, animal feed, and biological pesticides, emphasizing sustainable production processes at industrial scale.

City Therapeutics engineers enhanced small-interfering RNAs for RNAi therapeutics targeting liver, muscle, and CNS diseases from its Boston headquarters. Founded in 2023, the biopharma advances a pipeline of siRNA candidates improving delivery and potency, backed by ARCH Venture Partners and Takeda. Its platform conjugates lipids and GalNAc for extrahepatic tissue targeting in metabolic and neuromuscular disorders.

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Biocytogen is a biotechnology company offering end-to-end antibody discovery platforms using gene-edited RenMab mice and B-cell screening. Its services span humanized animal model creation, hybridoma sequencing, and bispecific antibody engineering for oncology and immunology targets. Headquartered in Beijing with US facilities in Wakefield, Massachusetts, Biocytogen partners with over 100 global pharmas including Takeda and Novartis, delivering candidates like fully human antibodies validated in cynomolgus models.

Brightseed is a San Francisco-based biosciences company using Forager AI to discover plant bioactives for health applications. The platform screens ingredients for compounds targeting inflammation and metabolic disorders, accelerating validation from years to months. It partners with Mars and ADM on formulations for supplements and foods. Founded in 2018, Brightseed analyzes seeds and herbs revealing novel molecules like those in fenugreek.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.